SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Common Stock Repurchased

Cash spent buying back the company's own shares.

SNDL Inc.NASDAQ: SNDL

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased declines year over year

Q1 FY2026 common stock repurchased of CA$9.58M (cash outflow) fell 36.3% year over year, ahead of the -65.0% change in trailing-twelve-month common stock repurchased. Sequentially, it rose 2949.4% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Common stock repurchased amounted to 1.6% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Common stock repurchased grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -36.3% holds above the trailing-twelve-month pace of -65.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$9.58M+2949.4% QoQ
Last fiscal yearDec 2025
-CA$15.35M+15.6% YoY
LTMMar 2026
-CA$9.89M-65.0% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.3%——
1 year+15.6%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

CAD · from the cash flow

Latest · FY2025
(15.35M) CAD
Year-over-year change
-15.6%

Common Stock Repurchased vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -65.0% is the 3rd highest of 4, against a peer median of +100.0%.
  • Common stock repurchased amounts to 1.1% of revenue for SNDL, versus a peer median of 0.0%.
SNDL Competitors
Common Stock Repurchased for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$33.9M USD—-32.8%5.0%
SNDLSNDL Inc.LTM Mar 2026CA$9.89M CAD-65.0%+4.7%1.1%
SIGASIGA Technologies, Inc.LTM Mar 2026$267.57K USD-66.8%—0.3%
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
ESPREsperion Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
EOLSEvolus, Inc.LTM Mar 2026$0 USD——0.0%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$0 USD+100.0%—0.0%
Peer median (excluding SNDL) —+100.0%-32.8%0.0%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(230.18M)(372.43M)(176.55M)(96.2M)(15.77M)
Depreciation & Amortization9.6M47.32M64.95M56.71M56.27M
Deferred Income Tax(2.27M)(7.34M)0(9.41M)0
Stock-Based Compensation12.31M9.67M15.4M20.04M13.91M
Change in Working Capital(1.53M)(22.07M)(32.88M)(7.45M)1.43M
Accounts Receivables00000
Inventory16.98M7.01M000
Accounts Payables00000
Other Working Capital(18.51M)(29.09M)(32.88M)(7.45M)1.43M
Other Non-Cash Items56.64M338.14M112.43M91.22M15.08M
Operating Cash Flow(155.44M)(6.71M)(16.65M)54.91M70.92M
Capital Expenditures(3.79M)(10.86M)(7.93M)(11.02M)(12.81M)
Acquisitions (Net)(478.34M)(147.78M)(21.39M)(39.48M)(3M)
Purchases of Investments(24.21M)(75.6M)(732K)0(16.41M)
Sales of Investments10.68M00045.58M
Other Investing Activities(612K)4.07M5.15M65.85M4.1M
Investing Cash Flow(496.28M)(230.16M)(24.82M)17.76M17.45M
Debt Repayment(10.36M)(37.69M)(41.01M)(36.95M)(39.25M)
Common Stock Issued1.06B22K000
Common Stock Repurchased0(13.39M)(1.54M)(13.28M)(15.35M)
Dividends Paid00000
Other Financing Activities97.65M9.27M(531K)871K106K
Financing Cash Flow1.15B(41.79M)(43.08M)(49.36M)(54.49M)
Effect of Forex Changes(9K)0000
Net Change in Cash497.88M(278.67M)(84.55M)23.32M33.88M
Free Cash Flow(159.23M)(17.57M)(24.58M)43.9M58.11M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.